サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1721220

核酸治療薬の世界市場：産業分析、規模、シェア、成長、動向、予測（2025年～2035年）

Nucleic Acid Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

出版日
ページ情報
英文 213 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.91円
核酸治療薬の世界市場：産業分析、規模、シェア、成長、動向、予測（2025年～2035年）
出版日: 2025年03月10日
発行: Transparency Market Research
ページ情報: 英文 213 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

核酸治療薬市場：調査範囲

TMRの調査レポート「核酸治療薬の世界市場」は、2025年～2035年の予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2025年を基準年、2035年を予測年として、2019年～2035年の世界の核酸治療薬市場の収益と予測を提供します。また、2025年～2035年の世界の核酸治療薬市場のCAGR%も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、核酸治療薬市場を推察しました。

市場スナップショット
2024年の市場規模 88億米ドル
2035年の市場規模 445億米ドル
CAGR 14.7%

当レポートでは、世界の核酸治療薬市場の競合情勢について調査しています。世界の核酸治療薬市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTが本レポートで紹介されている世界の核酸治療薬市場における企業の属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界の核酸治療薬市場の分析と予測（2020年～2035年）

第5章 主要洞察

  • 主要地域/国におけるヘルスケア費支出
  • 核酸治療薬産業における技術の進歩
  • FDA承認リスト
  • 核酸治療薬の価格動向
  • 核酸治療薬：臨床試験分析
  • 資金調達と投資分析
  • ポーターのファイブフォース分析
  • 主要地域/国における規制状況
  • 新規市場参入者のための市場開拓戦略
  • エンドユーザーにとっての主要な購入指標
  • 主要な業界イベント（パートナーシップ、コラボレーション、製品承認、合併、買収）
  • 主要競合が提供する製品のベンチマーク
  • 核酸治療薬の前臨床パイプライン解析

第6章 世界の市場分析と予測：治療タイプ別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：治療タイプ別（2020年～2035年）
    • アンチセンスオリゴヌクレオチド（ASO）
    • 低分子干渉RNA（siRNA）
    • 遺伝子治療
    • アプタマー
    • その他
  • 市場の魅力分析：治療タイプ別

第7章 世界の市場分析と予測：デリバリー方法別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：デリバリー方法別（2020年～2035年）
    • ウイルスベクターベースのデリバリーシステム
    • 非ウイルス性デリバリーシステム
  • 市場の魅力分析：デリバリー方法別

第8章 世界の市場分析と予測：投与経路別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：投与経路別（2020年～2035年）
    • 静脈内
    • 皮下
    • その他
  • 市場の魅力分析：投与経路別

第9章 世界の市場分析と予測：治療領域別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：治療領域別（2020年～2035年）
    • 神経筋疾患
    • 代謝障害
    • 心血管疾患
    • 眼科疾患
    • 腫瘍性疾患
    • その他
  • 市場の魅力分析：治療領域別

第10章 世界の市場分析と予測：エンドユーザー別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：エンドユーザー別（2020年～2035年）
    • 病院
    • 学術研究機関
    • その他
  • 市場の魅力分析：エンドユーザー別

第11章 世界の市場分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別（2020年～2035年）
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域別

第12章 北米の市場分析と予測

第13章 欧州の市場分析と予測

第14章 アジア太平洋の市場分析と予測

第15章 ラテンアメリカの市場分析と予測

第16章 中東・アフリカの市場分析と予測

第17章 競合情勢

  • 市場企業：競合マトリックス（企業階層別・規模別）
  • 市場シェア分析：企業別（2024年）
  • 企業プロファイル
    • Novartis AG
    • Pfizer, Inc.
    • Sanofi
    • Novo Nordisk A/S
    • AstraZeneca plc
    • Alnylam Pharmaceuticals, Inc.
    • Amgen Inc
    • Sarepta Therapeutics, Inc.
    • Bluebird Bio, Inc
    • CSL Behring LLC
    • Ferring Pharmaceuticals Inc.
    • Krystal Biotech, Inc.
    • PTC Therapeutics, Inc.
    • Jazz Pharmaceuticals plc
    • Astellas Pharma Inc.
図表

List of Tables

  • Table 01: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapy Type, 2020 - 2035
  • Table 02: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Delivery Method, 2020 - 2035
  • Table 03: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020 - 2035
  • Table 04: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 - 2035
  • Table 05: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By End-user, 2020 - 2035
  • Table 06: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Region, 2020 - 2035
  • Table 07: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country, 2020-2035
  • Table 08: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapy Type, 2020 - 2035
  • Table 09: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Delivery Method, 2020 - 2035
  • Table 10: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020 - 2035
  • Table 11: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 - 2035
  • Table 12: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By End-user, 2020 - 2035
  • Table 13: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020-2035
  • Table 14: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapy Type, 2020 - 2035
  • Table 15: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Delivery Method, 2020 - 2035
  • Table 16: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020 - 2035
  • Table 17: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 - 2035
  • Table 18: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By End-user, 2020 - 2035
  • Table 19: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020-2035
  • Table 20: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapy Type, 2020 - 2035
  • Table 21: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Delivery Method, 2020 - 2035
  • Table 22: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020 - 2035
  • Table 23: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 - 2035
  • Table 24: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By End-user, 2020 - 2035
  • Table 25: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020-2035
  • Table 26: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapy Type, 2020 - 2035
  • Table 27: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Delivery Method, 2020 - 2035
  • Table 28: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020 - 2035
  • Table 29: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 - 2035
  • Table 30: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By End-user, 2020 - 2035
  • Table 31: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020-2035
  • Table 32: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapy Type, 2020 - 2035
  • Table 33: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Delivery Method, 2020 - 2035
  • Table 34: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020 - 2035
  • Table 35: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 - 2035
  • Table 36: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By End-user, 2020 - 2035

List of Figures

  • Figure 01: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, 2020 - 2035
  • Figure 02: Global Nucleic Acid Therapeutics Market Value Share Analysis, By Therapy Type, 2024 and 2035
  • Figure 03: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapy Type, 2025 - 2035
  • Figure 04: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Antisense oligonucleotides (ASOs), 2020 - 2035
  • Figure 05: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Small interfering RNA (siRNA), 2020 - 2035
  • Figure 06: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Gene Therapies, 2020 - 2035
  • Figure 07: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Aptamers, 2020 - 2035
  • Figure 08: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Others, 2020 - 2035
  • Figure 09: Global Nucleic Acid Therapeutics Market Value Share Analysis, By Delivery Method, 2024 and 2035
  • Figure 10: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, By Delivery Method, 2025 - 2035
  • Figure 11: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Viral vector-based Delivery Systems, 2020 - 2035
  • Figure 12: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Non-viral Delivery Systems, 2020 - 2035
  • Figure 13: Global Nucleic Acid Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 14: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 - 2035
  • Figure 15: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Intravenous, 2020 - 2035
  • Figure 16: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Subcutaneous, 2020 - 2035
  • Figure 17: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Others, 2020 - 2035
  • Figure 18: Global Nucleic Acid Therapeutics Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
  • Figure 19: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapeutic Area, 2025 - 2035
  • Figure 20: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Neuromuscular Disorder, 2020 - 2035
  • Figure 21: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Metabolic Disorders, 2020 - 2035
  • Figure 22: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Cardiovascular Disorders, 2020 - 2035
  • Figure 23: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Ophthalmological Disorders, 2020 - 2035
  • Figure 24: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Oncological Disorders, 2020 - 2035
  • Figure 25: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Others, 2020 - 2035
  • Figure 26: Global Nucleic Acid Therapeutics Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 27: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, By End-user, 2025 - 2035
  • Figure 28: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Hospitals, 2020 - 2035
  • Figure 29: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Academic and Research Institutes, 2020 - 2035
  • Figure 30: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Others, 2020 - 2035
  • Figure 31: Global Nucleic Acid Therapeutics Market Value Share Analysis, By Region, 2024 and 2035
  • Figure 32: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, By Region, 2025 - 2035
  • Figure 33: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, 2020 - 2035
  • Figure 34: North America Nucleic Acid Therapeutics Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 35: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country, 2025 - 2035
  • Figure 36: North America Nucleic Acid Therapeutics Market Value Share Analysis, By Therapy Type, 2024 and 2035
  • Figure 37: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapy Type, 2025 - 2035
  • Figure 38: North America Nucleic Acid Therapeutics Market Value Share Analysis, By Delivery Method, 2024 and 2035
  • Figure 39: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Delivery Method, 2025 - 2035
  • Figure 40: North America Nucleic Acid Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 41: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 - 2035
  • Figure 42: North America Nucleic Acid Therapeutics Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
  • Figure 43: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapeutic Area, 2025 - 2035
  • Figure 44: North America Nucleic Acid Therapeutics Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 45: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, By End-user, 2025 - 2035
  • Figure 46: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, 2020 - 2035
  • Figure 47: Europe Nucleic Acid Therapeutics Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
  • Figure 48: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country / Sub-region, 2025 - 2035
  • Figure 49: Europe Nucleic Acid Therapeutics Market Value Share Analysis, By Therapy Type, 2024 and 2035
  • Figure 50: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapy Type, 2025 - 2035
  • Figure 51: Europe Nucleic Acid Therapeutics Market Value Share Analysis, By Delivery Method, 2024 and 2035
  • Figure 52: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, By Delivery Method, 2025 - 2035
  • Figure 53: Europe Nucleic Acid Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 54: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 - 2035
  • Figure 55: Europe Nucleic Acid Therapeutics Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
  • Figure 56: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapeutic Area, 2025 - 2035
  • Figure 57: Europe Nucleic Acid Therapeutics Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 58: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, By End-user, 2025 - 2035
  • Figure 59: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, 2020 - 2035
  • Figure 60: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 61: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2025 - 2035
  • Figure 62: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, By Therapy Type, 2024 and 2035
  • Figure 63: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapy Type, 2025 - 2035
  • Figure 64: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, By Delivery Method, 2024 and 2035
  • Figure 65: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, By Delivery Method, 2025 - 2035
  • Figure 66: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 67: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 - 2035
  • Figure 68: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
  • Figure 69: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapeutic Area, 2025 - 2035
  • Figure 70: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 71: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, By End-user, 2025 - 2035
  • Figure 72: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, 2020 - 2035
  • Figure 73: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
  • Figure 74: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country / Sub-region, 2025 - 2035
  • Figure 75: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, By Therapy Type, 2024 and 2035
  • Figure 76: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapy Type, 2025 - 2035
  • Figure 77: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, By Delivery Method, 2024 and 2035
  • Figure 78: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Delivery Method, 2025 - 2035
  • Figure 79: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 80: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 - 2035
  • Figure 81: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
  • Figure 82: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapeutic Area, 2025 - 2035
  • Figure 83: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 84: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, By End-user, 2025 - 2035
  • Figure 85: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, 2020 - 2035
  • Figure 86: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
  • Figure 87: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country / Sub-region, 2025 - 2035
  • Figure 88: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, By Therapy Type, 2024 and 2035
  • Figure 89: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapy Type, 2025 - 2035
  • Figure 90: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, By Delivery Method, 2024 and 2035
  • Figure 91: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, By Delivery Method, 2025 - 2035
  • Figure 92: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 93: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 - 2035
  • Figure 94: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
  • Figure 95: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapeutic Area, 2025 - 2035
  • Figure 96: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 97: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, By End-user, 2025 - 2035
目次
Product Code: TMRGL86333

Nucleic Acid Therapeutics Market - Scope of Report

TMR's report on the global nucleic acid therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global nucleic acid therapeutics market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global nucleic acid therapeutics market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the nucleic acid therapeutics market.

Market Snapshot
Market Value in 2024US$ 8.8 Bn
Market Value in 2035US$ 44.5 Bn
CAGR14.7%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global nucleic acid therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global nucleic acid therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global nucleic acid therapeutics market.

The report delves into the competitive landscape of the global nucleic acid therapeutics market. Key players operating in the global nucleic acid therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global nucleic acid therapeutics market profiled in this report.

Key Questions Answered in Global nucleic acid therapeutics market Report:

  • What is the sales/revenue generated by nucleic acid therapeutics across all regions during the forecast period?
  • What are the opportunities in the global nucleic acid therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2035?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Nucleic Acid Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global nucleic acid therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global nucleic acid therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global nucleic acid therapeutics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Nucleic Acid Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Nucleic Acid Therapeutics Market Analysis and Forecast, 2020 - 2035
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Healthcare Expenditure across Key Regions / Countries
  • 5.2. Technological Advancements in Nucleic Acid Therapeutics Industry
  • 5.3. List of Nucleic Acid Therapeutics Approved by FDA
  • 5.4. Nucleic Acid Therapeutics Pricing Trends
  • 5.5. Nucleic Acid Therapeutics: Clinical Trial Analysis
  • 5.6. Funding and Investments Analysis
  • 5.7. PORTER's Five Forces Analysis
  • 5.8. Regulatory Landscape across Key Regions / Countries
  • 5.9. Go-to-Market Strategy for New Market Entrants
  • 5.10. Key Purchase Metrics for End-users
  • 5.11. Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions)
  • 5.12. Benchmarking of the Products Offered by the Leading Competitors
  • 5.13. Preclinical Pipeline Analysis for Nucleic Acid Therapeutics

6. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by Therapy Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Therapy Type, 2020 - 2035
    • 6.3.1. Antisense oligonucleotides (ASOs)
    • 6.3.2. Small interfering R(siRNA)
    • 6.3.3. Gene Therapies
    • 6.3.4. Aptamers
    • 6.3.5. Others
  • 6.4. Market Attractiveness Analysis, by Therapy Type

7. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by Delivery Method

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Delivery Method, 2020 - 2035
    • 7.3.1. Viral vector-based Delivery Systems
    • 7.3.2. Non-viral Delivery Systems
  • 7.4. Market Attractiveness Analysis, by Delivery Method

8. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2020 - 2035
    • 8.3.1. Intravenous
    • 8.3.2. Subcutaneous
    • 8.3.3. Others
  • 8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by Therapeutic Area

  • 9.1. Introduction & Definition
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Therapeutic Area, 2020 - 2035
    • 9.3.1. Neuromuscular Disorder
    • 9.3.2. Metabolic Disorders
    • 9.3.3. Cardiovascular Disorders
    • 9.3.4. Ophthalmological Disorders
    • 9.3.5. Oncological Disorders
    • 9.3.6. Others
  • 9.4. Market Attractiveness Analysis, by Therapeutic Area

10. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by End-user

  • 10.1. Introduction & Definition
  • 10.2. Key Findings/Developments
  • 10.3. Market Value Forecast, by End-user, 2020 - 2035
    • 10.3.1. Hospitals
    • 10.3.2. Academic and Research Institutes
    • 10.3.3. Others
  • 10.4. Market Attractiveness Analysis, by End-user

11. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by Region

  • 11.1. Key Findings
  • 11.2. Market Value Forecast, by Region, 2020 - 2035
    • 11.2.1. North America
    • 11.2.2. Europe
    • 11.2.3. Asia Pacific
    • 11.2.4. Latin America
    • 11.2.5. Middle East & Africa
  • 11.3. Market Attractiveness Analysis, by Region

12. North America Nucleic Acid Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Therapy Type, 2020 - 2035
    • 12.2.1. Antisense oligonucleotides (ASOs)
    • 12.2.2. Small interfering R(siRNA)
    • 12.2.3. Gene Therapies
    • 12.2.4. Aptamers
    • 12.2.5. Others
  • 12.3. Market Value Forecast, by Delivery Method, 2020 - 2035
    • 12.3.1. Viral vector-based Delivery Systems
    • 12.3.2. Non-viral Delivery Systems
  • 12.4. Market Value Forecast, by Route of Administration, 2020 - 2035
    • 12.4.1. Intravenous
    • 12.4.2. Subcutaneous
    • 12.4.3. Others
  • 12.5. Market Value Forecast, by Therapeutic Area, 2020 - 2035
    • 12.5.1. Neuromuscular Disorder
    • 12.5.2. Metabolic Disorders
    • 12.5.3. Cardiovascular Disorders
    • 12.5.4. Ophthalmological Disorders
    • 12.5.5. Oncological Disorders
    • 12.5.6. Others
  • 12.6. Market Value Forecast, by End-user, 2020 - 2035
    • 12.6.1. Hospitals
    • 12.6.2. Academic and Research Institutes
    • 12.6.3. Others
  • 12.7. Market Value Forecast, by Country, 2020 - 2035
    • 12.7.1. U.S.
    • 12.7.2. Canada
  • 12.8. Market Attractiveness Analysis
    • 12.8.1. By Therapy Type
    • 12.8.2. By Delivery Method
    • 12.8.3. By Route of Administration
    • 12.8.4. By Therapeutic Area
    • 12.8.5. By End-user
    • 12.8.6. By Country

13. Europe Nucleic Acid Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Therapy Type, 2020 - 2035
    • 13.2.1. Antisense oligonucleotides (ASOs)
    • 13.2.2. Small interfering R(siRNA)
    • 13.2.3. Gene Therapies
    • 13.2.4. Aptamers
    • 13.2.5. Others
  • 13.3. Market Value Forecast, by Delivery Method, 2020 - 2035
    • 13.3.1. Viral vector-based Delivery Systems
    • 13.3.2. Non-viral Delivery Systems
  • 13.4. Market Value Forecast, by Route of Administration, 2020 - 2035
    • 13.4.1. Intravenous
    • 13.4.2. Subcutaneous
    • 13.4.3. Others
  • 13.5. Market Value Forecast, by Therapeutic Area, 2020 - 2035
    • 13.5.1. Neuromuscular Disorder
    • 13.5.2. Metabolic Disorders
    • 13.5.3. Cardiovascular Disorders
    • 13.5.4. Ophthalmological Disorders
    • 13.5.5. Oncological Disorders
    • 13.5.6. Others
  • 13.6. Market Value Forecast, by End-user, 2020 - 2035
    • 13.6.1. Hospitals
    • 13.6.2. Academic and Research Institutes
    • 13.6.3. Others
  • 13.7. Market Value Forecast, by Country/Sub-region, 2020 - 2035
    • 13.7.1. Germany
    • 13.7.2. UK
    • 13.7.3. France
    • 13.7.4. Italy
    • 13.7.5. Spain
    • 13.7.6. Rest of Europe
  • 13.8. Market Attractiveness Analysis
    • 13.8.1. By Therapy Type
    • 13.8.2. By Delivery Method
    • 13.8.3. By Route of Administration
    • 13.8.4. By Therapeutic Area
    • 13.8.5. By End-user
    • 13.8.6. By Country/Sub-region

14. Asia Pacific Nucleic Acid Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Therapy Type, 2020 - 2035
    • 14.2.1. Antisense oligonucleotides (ASOs)
    • 14.2.2. Small interfering R(siRNA)
    • 14.2.3. Gene Therapies
    • 14.2.4. Aptamers
    • 14.2.5. Others
  • 14.3. Market Value Forecast, by Delivery Method, 2020 - 2035
    • 14.3.1. Viral vector-based Delivery Systems
    • 14.3.2. Non-viral Delivery Systems
  • 14.4. Market Value Forecast, by Route of Administration, 2020 - 2035
    • 14.4.1. Intravenous
    • 14.4.2. Subcutaneous
    • 14.4.3. Others
  • 14.5. Market Value Forecast, by Therapeutic Area, 2020 - 2035
    • 14.5.1. Neuromuscular Disorder
    • 14.5.2. Metabolic Disorders
    • 14.5.3. Cardiovascular Disorders
    • 14.5.4. Ophthalmological Disorders
    • 14.5.5. Oncological Disorders
    • 14.5.6. Others
  • 14.6. Market Value Forecast, by End-user, 2020 - 2035
    • 14.6.1. Hospitals
    • 14.6.2. Academic and Research Institutes
    • 14.6.3. Others
  • 14.7. Market Value Forecast, by Country/Sub-region, 2020 - 2035
    • 14.7.1. China
    • 14.7.2. Japan
    • 14.7.3. India
    • 14.7.4. Australia & New Zealand
    • 14.7.5. Rest of Asia Pacific
  • 14.8. Market Attractiveness Analysis
    • 14.8.1. By Therapy Type
    • 14.8.2. By Delivery Method
    • 14.8.3. By Route of Administration
    • 14.8.4. By Therapeutic Area
    • 14.8.5. By End-user
    • 14.8.6. By Country/Sub-region

15. Latin America Nucleic Acid Therapeutics Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Therapy Type, 2020 - 2035
    • 15.2.1. Antisense oligonucleotides (ASOs)
    • 15.2.2. Small interfering R(siRNA)
    • 15.2.3. Gene Therapies
    • 15.2.4. Aptamers
    • 15.2.5. Others
  • 15.3. Market Value Forecast, by Delivery Method, 2020 - 2035
    • 15.3.1. Viral vector-based Delivery Systems
    • 15.3.2. Non-viral Delivery Systems
  • 15.4. Market Value Forecast, by Route of Administration, 2020 - 2035
    • 15.4.1. Intravenous
    • 15.4.2. Subcutaneous
    • 15.4.3. Others
  • 15.5. Market Value Forecast, by Therapeutic Area, 2020 - 2035
    • 15.5.1. Neuromuscular Disorder
    • 15.5.2. Metabolic Disorders
    • 15.5.3. Cardiovascular Disorders
    • 15.5.4. Ophthalmological Disorders
    • 15.5.5. Oncological Disorders
    • 15.5.6. Others
  • 15.6. Market Value Forecast, by End-user, 2020 - 2035
    • 15.6.1. Hospitals
    • 15.6.2. Academic and Research Institutes
    • 15.6.3. Others
  • 15.7. Market Value Forecast, by Country/Sub-region, 2020 - 2035
    • 15.7.1. Brazil
    • 15.7.2. Mexico
    • 15.7.3. Rest of Latin America
  • 15.8. Market Attractiveness Analysis
    • 15.8.1. By Therapy Type
    • 15.8.2. By Delivery Method
    • 15.8.3. By Route of Administration
    • 15.8.4. By Therapeutic Area
    • 15.8.5. By End-user
    • 15.8.6. By Country/Sub-region

16. Middle East & Africa Nucleic Acid Therapeutics Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value Forecast, by Therapy Type, 2020 - 2035
    • 16.2.1. Antisense oligonucleotides (ASOs)
    • 16.2.2. Small interfering R(siRNA)
    • 16.2.3. Gene Therapies
    • 16.2.4. Aptamers
    • 16.2.5. Others
  • 16.3. Market Value Forecast, by Delivery Method, 2020 - 2035
    • 16.3.1. Viral vector-based Delivery Systems
    • 16.3.2. Non-viral Delivery Systems
  • 16.4. Market Value Forecast, by Route of Administration, 2020 - 2035
    • 16.4.1. Intravenous
    • 16.4.2. Subcutaneous
    • 16.4.3. Others
  • 16.5. Market Value Forecast, by Therapeutic Area, 2020 - 2035
    • 16.5.1. Neuromuscular Disorder
    • 16.5.2. Metabolic Disorders
    • 16.5.3. Cardiovascular Disorders
    • 16.5.4. Ophthalmological Disorders
    • 16.5.5. Oncological Disorders
    • 16.5.6. Others
  • 16.6. Market Value Forecast, by End-user, 2020 - 2035
    • 16.6.1. Hospitals
    • 16.6.2. Academic and Research Institutes
    • 16.6.3. Others
  • 16.7. Market Value Forecast, by Country/Sub-region, 2020 - 2035
    • 16.7.1. GCC Countries
    • 16.7.2. South Africa
    • 16.7.3. Rest of Middle East & Africa
  • 16.8. Market Attractiveness Analysis
    • 16.8.1. By Therapy Type
    • 16.8.2. By Delivery Method
    • 16.8.3. By Route of Administration
    • 16.8.4. By Therapeutic Area
    • 16.8.5. By End-user
    • 16.8.6. By Country/Sub-region

17. Competition Landscape

  • 17.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 17.2. Market Share Analysis, by Company (2024)
  • 17.3. Company Profiles
    • 17.3.1. Novartis AG
      • 17.3.1.1. Company Overview
      • 17.3.1.2. Financial Overview
      • 17.3.1.3. Product Portfolio
      • 17.3.1.4. Business Strategies
      • 17.3.1.5. Recent Developments
    • 17.3.2. Pfizer, Inc.
      • 17.3.2.1. Company Overview
      • 17.3.2.2. Financial Overview
      • 17.3.2.3. Product Portfolio
      • 17.3.2.4. Business Strategies
      • 17.3.2.5. Recent Developments
    • 17.3.3. Sanofi
      • 17.3.3.1. Company Overview
      • 17.3.3.2. Financial Overview
      • 17.3.3.3. Product Portfolio
      • 17.3.3.4. Business Strategies
      • 17.3.3.5. Recent Developments
    • 17.3.4. Novo Nordisk A/S
      • 17.3.4.1. Company Overview
      • 17.3.4.2. Financial Overview
      • 17.3.4.3. Product Portfolio
      • 17.3.4.4. Business Strategies
      • 17.3.4.5. Recent Developments
    • 17.3.5. AstraZeneca plc
      • 17.3.5.1. Company Overview
      • 17.3.5.2. Financial Overview
      • 17.3.5.3. Product Portfolio
      • 17.3.5.4. Business Strategies
      • 17.3.5.5. Recent Developments
    • 17.3.6. Alnylam Pharmaceuticals, Inc.
      • 17.3.6.1. Company Overview
      • 17.3.6.2. Financial Overview
      • 17.3.6.3. Product Portfolio
      • 17.3.6.4. Business Strategies
      • 17.3.6.5. Recent Developments
    • 17.3.7. Amgen Inc
      • 17.3.7.1. Company Overview
      • 17.3.7.2. Financial Overview
      • 17.3.7.3. Product Portfolio
      • 17.3.7.4. Business Strategies
      • 17.3.7.5. Recent Developments
    • 17.3.8. Sarepta Therapeutics, Inc.
      • 17.3.8.1. Company Overview
      • 17.3.8.2. Financial Overview
      • 17.3.8.3. Product Portfolio
      • 17.3.8.4. Business Strategies
      • 17.3.8.5. Recent Developments
    • 17.3.9. Bluebird Bio, Inc
      • 17.3.9.1. Company Overview
      • 17.3.9.2. Financial Overview
      • 17.3.9.3. Product Portfolio
      • 17.3.9.4. Business Strategies
      • 17.3.9.5. Recent Developments
    • 17.3.10. CSL Behring LLC
      • 17.3.10.1. Company Overview
      • 17.3.10.2. Financial Overview
      • 17.3.10.3. Product Portfolio
      • 17.3.10.4. Business Strategies
      • 17.3.10.5. Recent Developments
    • 17.3.11. Ferring Pharmaceuticals Inc.
      • 17.3.11.1. Company Overview
      • 17.3.11.2. Financial Overview
      • 17.3.11.3. Product Portfolio
      • 17.3.11.4. Business Strategies
      • 17.3.11.5. Recent Developments
    • 17.3.12. Krystal Biotech, Inc.
      • 17.3.12.1. Company Overview
      • 17.3.12.2. Financial Overview
      • 17.3.12.3. Product Portfolio
      • 17.3.12.4. Business Strategies
      • 17.3.12.5. Recent Developments
    • 17.3.13. PTC Therapeutics, Inc.
      • 17.3.13.1. Company Overview
      • 17.3.13.2. Financial Overview
      • 17.3.13.3. Product Portfolio
      • 17.3.13.4. Business Strategies
      • 17.3.13.5. Recent Developments
    • 17.3.14. Jazz Pharmaceuticals plc
      • 17.3.14.1. Company Overview
      • 17.3.14.2. Financial Overview
      • 17.3.14.3. Product Portfolio
      • 17.3.14.4. Business Strategies
      • 17.3.14.5. Recent Developments
    • 17.3.15. Astellas Pharma Inc.
      • 17.3.15.1. Company Overview
      • 17.3.15.2. Financial Overview
      • 17.3.15.3. Product Portfolio
      • 17.3.15.4. Business Strategies
      • 17.3.15.5. Recent Developments